Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03091257 · ClinicalTrials.gov registry record · Phase 1

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT03091257: Active Phase 1 study of Multiple Myeloma, sponsored by Massachusetts General Hospital.

NCT03091257 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03091257, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib

Primary Outcome

Response rate by IMWG criteria

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Trametinib
  • DRUG Dabrafenib

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-06-21
Est. Completion 2026-09-15
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT03091257 still lists

NCT03091257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.

NCT03091257 reports a single indexed study location in Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT03091257 about?

NCT03091257 is a clinical study titled "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma". This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib

What is the current status of trial NCT03091257?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-06-21. Estimated completion is 2026-09-15.

What conditions does trial NCT03091257 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03091257?

The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG).

Who is sponsoring clinical trial NCT03091257?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03091257 being conducted?

This trial has 2 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03091257's enrollment target sits among peer trials

30 338th of 438 higher than 80 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03091257, the US trial registry maintained by the National Library of Medicine. NCT03091257 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.